Bifogade filer
Kurs
-1,79%
Likviditet
1,24 MSEK
Prenumeration
Kalender
Tid* | ||
2025-05-13 | 07:00 | Kvartalsrapport 2025-Q1 |
2025-02-21 | 07:00 | Bokslutskommuniké 2024 |
2024-12-02 | - | Extra Bolagsstämma 2025 |
2024-11-15 | - | Kvartalsrapport 2024-Q3 |
2024-08-28 | - | Kvartalsrapport 2024-Q2 |
2024-05-24 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
2024-05-23 | - | Årsstämma |
2024-05-21 | - | Kvartalsrapport 2024-Q1 |
2024-02-22 | - | Bokslutskommuniké 2023 |
2023-11-10 | - | Kvartalsrapport 2023-Q3 |
2023-08-22 | - | Kvartalsrapport 2023-Q2 |
2023-05-24 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
2023-05-23 | - | Årsstämma |
2023-05-23 | - | Kvartalsrapport 2023-Q1 |
2023-02-23 | - | Bokslutskommuniké 2022 |
2022-11-10 | - | Kvartalsrapport 2022-Q3 |
2022-08-30 | - | Kvartalsrapport 2022-Q2 |
2022-07-21 | - | Extra Bolagsstämma 2022 |
2022-05-24 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
2022-05-23 | - | Årsstämma |
2022-05-23 | - | Kvartalsrapport 2022-Q1 |
2022-02-24 | - | Bokslutskommuniké 2021 |
2021-11-11 | - | Kvartalsrapport 2021-Q3 |
2021-08-19 | - | Kvartalsrapport 2021-Q2 |
2021-05-27 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
2021-05-26 | - | Årsstämma |
2021-05-26 | - | Kvartalsrapport 2021-Q1 |
2021-02-25 | - | Bokslutskommuniké 2020 |
2020-11-12 | - | Kvartalsrapport 2020-Q3 |
2020-10-13 | - | Extra Bolagsstämma 2020 |
2020-08-20 | - | Kvartalsrapport 2020-Q2 |
2020-05-28 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
2020-05-27 | - | Årsstämma |
2020-05-27 | - | Kvartalsrapport 2020-Q1 |
2020-02-27 | - | Bokslutskommuniké 2019 |
2019-11-15 | - | Kvartalsrapport 2019-Q3 |
2019-08-22 | - | Kvartalsrapport 2019-Q2 |
2019-05-28 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
2019-05-27 | - | Årsstämma |
2019-05-27 | - | Kvartalsrapport 2019-Q1 |
2019-02-27 | - | Bokslutskommuniké 2018 |
2018-11-15 | - | Kvartalsrapport 2018-Q3 |
2018-08-21 | - | Kvartalsrapport 2018-Q2 |
2018-06-01 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
2018-05-31 | - | Årsstämma |
2018-05-15 | - | Kvartalsrapport 2018-Q1 |
2018-02-28 | - | Bokslutskommuniké 2017 |
2017-11-15 | - | Kvartalsrapport 2017-Q3 |
2017-08-23 | - | Kvartalsrapport 2017-Q2 |
2017-05-31 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
2017-05-30 | - | Årsstämma |
2017-05-15 | - | Kvartalsrapport 2017-Q1 |
2017-03-15 | - | Bokslutskommuniké 2016 |
2017-01-16 | - | Extra Bolagsstämma 2017 |
2016-11-21 | - | Kvartalsrapport 2016-Q3 |
2016-08-24 | - | Kvartalsrapport 2016-Q2 |
2016-05-25 | - | Årsstämma |
2016-05-16 | - | Kvartalsrapport 2016-Q1 |
2016-03-02 | - | X-dag ordinarie utdelning CANTA 0.00 SEK |
2016-03-01 | - | Bokslutskommuniké 2015 |
2015-11-17 | - | Kvartalsrapport 2015-Q3 |
2015-08-25 | - | Kvartalsrapport 2015-Q2 |
2015-05-19 | - | Kvartalsrapport 2015-Q1 |
2015-03-03 | - | Bokslutskommuniké 2014 |
Beskrivning
Land | Sverige |
---|---|
Lista | Small Cap Stockholm |
Sektor | Hälsovård |
Industri | Bioteknik |
Cantargia AB will publish the company’s year-end report for 2023 on Thursday, February 22, 2024, at 07:00 a.m. CET.
In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on February 22, at 3:00 p.m. CET, where Cantargia’s CEO, Göran Forsberg, and CFO, Patrik Renblad, will present Cantargia and comment on the year-end report, followed by a Q&A-session.
If you wish to participate via webcast, please use the link below. Via the webcast you will be able to ask written questions. Webcast: https://ir.financialhearings.com/cantargia-q4-report-2023
If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference: https://conference.financialhearings.com/teleconference/?id=50047304
The webcast will also be available on demand on Cantargia’s corporate website: http://www.cantargia.com
For further information, please contact
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com
About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The main program, the antibody nadunolimab (CAN04), is being studied clinically primarily in combination with chemotherapy with a focus on pancreatic cancer, non-small cell lung cancer and triple-negative breast cancer. Positive interim data for the combinations indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second development program, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.
Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.